No evidence of a differential treatment effect with omalizumab versus placebo across baseline IgE level and BMI subgroups in patients with chronic spontaneous urticaria

Affiliations

• ¹ Department of Medicine, Endeavor Health, Glenview, Ill.
• ² Division of Rheumatology, Allergy & Immunology, University of Cincinnati, Cincinnati, Ohio.
• ³ Genentech, Inc., South San Francisco, Calif. Electronic address: holden.michael@gene.com.
• ⁴ Genentech, Inc., South San Francisco, Calif.
• ⁵ Division of Allergy and Immunology, University of South Florida, Tampa, Fla.